¼¼°èÀÇ È¯ÀÚ Âü¿© ±â¼ú ½ÃÀå
Patient Engagement Technology
»óǰÄÚµå : 1793691
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 378 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,183,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,550,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ȯÀÚ Âü¿© ±â¼ú ¼¼°è ½ÃÀåÀº 2030³â±îÁö 804¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 275¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ȯÀÚ Âü¿© ±â¼ú ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 19.6%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 804¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ¼ÒÇÁÆ®¿þ¾î ±¸¼º¿ä¼Ò´Â CAGR 19.0%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 448¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¼­ºñ½º ±¸¼º¿ä¼Ò ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ CAGR·Î 20.9%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 75¾ï ´Þ·¯, Áß±¹Àº CAGR 26.3%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹Ãø

¹Ì±¹ÀÇ È¯ÀÚ Âü¿© ±â¼ú ½ÃÀåÀº 2024³â¿¡ 75¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 188¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 26.3%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, °¢°¢ ºÐ¼® ±â°£ µ¿¾È¿¡ 15.7%¿Í 17.5%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 16.4%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ È¯ÀÚ Âü¿© ±â¼ú ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ȯÀÚ Âü¿© ±â¼úÀÌ Çö´ë ÀÇ·á ¼­ºñ½º Á¦°øÀÇ ±â¹ÝÀÌ µÇ°í ÀÖ´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

ȯÀÚ Âü¿© ±â¼úÀ̶õ ȯÀÚ¿Í ÀÇ·áÁøÀÇ ¾ç¹æÇâ ¼ÒÅëÀ» ÃËÁøÇÏ´Â µðÁöÅÐ µµ±¸ ¹× Ç÷§ÆûÀ» ÀǹÌÇϸç, Á¤º¸¿¡ ±â¹ÝÇÑ ÀÇ»ç°áÁ¤°ú Ä¡·á¿¡ ´ëÇÑ Àû±ØÀûÀÎ Âü¿©¸¦ ÅëÇØ °Ç°­ »óÅÂÀÇ °³¼±À» ¸ñÇ¥·Î ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú¿¡´Â ȯÀÚ Æ÷ÅÐ, ¸ð¹ÙÀÏ °Ç°­ ¾Û, ÀÚµ¿ ¾Ë¸², °¡»ó Áø·á Ç÷§Æû, ¿ø°Ý ¸ð´ÏÅ͸µ ÀÎÅÍÆäÀ̽º µîÀÌ Æ÷ÇԵ˴ϴÙ. ±× ÇÙ½É ±â´ÉÀº ¿¹¹æ, Áø´Ü, Ä¡·á, ÈÄ¼Ó Á¶Ä¡ÀÇ °¢ ´Ü°è¿¡ °ÉÃÄ È¯ÀÚ¿¡°Ô Á¤º¸¸¦ Á¦°øÇϰí, µ¿±â¸¦ ºÎ¿©Çϰí, Ä¡·áÀÇ ÆäÀ̽¼Æ® ¿©Á¤¿¡ Âü¿©Çϵµ·Ï ÇÏ´Â °ÍÀÔ´Ï´Ù.

ÀÇ·á ½Ã½ºÅÛÀÌ ¾ç ±â¹Ý¿¡¼­ °¡Ä¡ ±â¹Ý Áø·á ¸ðµ¨·Î ÀüȯÇÔ¿¡ µû¶ó ȯÀÚ Âü¿©´Â Áø·áÀÇ Áú, ±ÔÁ¤ Áؼö ¹× ÀÚ¿ø È¿À²¼ºÀÇ Áß¿äÇÑ ¿øµ¿·ÂÀ¸·Î Àνĵǰí ÀÖ½À´Ï´Ù. ÇöÀç ±â¼úÀº ¿¹¾à ¿¹¾à, °³º°È­µÈ ±³À°, º¹¾à ¼øÀÀµµ ÃßÀû, °Ë»ç °á°ú¿¡ ´ëÇÑ Á¢±Ù µîÀÇ ¾÷¹«¸¦ Áö¿øÇϰí ÀÖ½À´Ï´Ù. ƯÈ÷ ¿Ü·¡ ¹× ¸¸¼ºÁúȯ °ü¸®ÀÚÀÇ ºÎ´ãÀ» ÁÙÀ̸鼭 ȯÀÚ¿¡°Ô ±ÇÇÑÀ» ºÎ¿©ÇÒ ¼ö Àֱ⠶§¹®¿¡ ÀÇ·á ¼­ºñ½º Á¦°øÀÚ´Â ÀÓ»ó ¿öÅ©Ç÷ο쿡 Âü¿© µµ±¸¸¦ ÅëÇÕÇÏ´Â °ÍÀ» ±ÇÀåÇϰí ÀÖ½À´Ï´Ù.

ÅëÇÕ, ÀÚµ¿È­, °³ÀÎÈ­¸¦ ÅëÇØ Âü¿© µµ±¸´Â ¾î¶»°Ô ÁøÈ­Çϰí Àִ°¡?

µðÁöÅÐ Çコ Ç÷§ÆûÀÇ ¹ßÀüÀ¸·Î ȯÀÚ Âü¿© µµ±¸´Â ´õ¿í ÅëÇÕÀûÀ̰í Áö´ÉÀûÀ̸ç ÀûÀÀ·ÂÀÌ ¶Ù¾î³ª¸ç, ȯÀÚ Âü¿© µµ±¸´Â ´õ¿í Áö´ÉÀûÀ̰í ÀûÀÀ·ÂÀÌ ¶Ù¾î³³´Ï´Ù. ÀüÀÚ ÀÇ·á ±â·Ï(EHR)°úÀÇ »óÈ£ ¿î¿ë¼ºÀ» ÅëÇØ ȯÀÚ´Â ÀÚ½ÅÀÇ ÀÇ·á ±â·Ï¿¡ ¾×¼¼½ºÇϰí ÀÇ·áÁø°ú Á÷Á¢ ¼ÒÅëÇÒ ¼ö ÀÖ½À´Ï´Ù. ¸ð¹ÙÀÏ ¾Û°ú ¿þ¾î·¯ºíÀº ½Ç½Ã°£ Çǵå¹é ¹× Çൿ ÃßÀû ±â´ÉÀ¸·Î ¼³°èµÇ¾î ÀÏ»óÀûÀÎ °Ç°­ °ü¸®¸¦ º¸´Ù Æí¸®ÇÏ°í µ¥ÀÌÅÍ ±â¹ÝÀûÀ¸·Î °ü¸®ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù.

AI ±â¹Ý 꺿, °¡»ó ºñ¼­, À½¼º ±â¹Ý ÀÎÅÍÆäÀ̽º´Â Áö¼ÓÀûÀΠȯÀÚ Áö¿øÀ» Á¦°øÇÏ°í ´ë¸é Áø·á¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ³·Ãß±â À§ÇØ µµÀԵǰí ÀÖ½À´Ï´Ù. ȯÀÚÀÇ º´·Â, »óÅÂ, ¼±È£µµ¿¡ ±â¹ÝÇÑ °³ÀÎÈ­µÈ Ä¿¹Â´ÏÄÉÀ̼ǰú ±³À° ÄÁÅÙÃ÷´Â °ü·Ã¼º°ú ¹ÝÀÀ·üÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. ¸®¸¶Àδõ, ¼·Ãë ¾ç½Ä, ¸¸Á·µµ Á¶»ç ÀÚµ¿È­´Â ȯÀÚ¿ÍÀÇ °ü°è¸¦ À¯ÁöÇϸ鼭 ÀÓ»ó °ü¸®¸¦ °£¼ÒÈ­ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ, ´Ù±¹¾î Áö¿ø°ú Á¢±Ù¼º ±â´ÉÀº ´Ù¾çÇÑ »ç¶÷µéÀÇ Âü¿©¿Í Âü¿©¸¦ È®´ëÇϰí ÀÖ½À´Ï´Ù.

¼ö¿ä°¡ Áõ°¡ÇÏ´Â °÷, ȯÀÚ Âü¿©°¡ ¿ì¼±½ÃµÇ´Â ÀÇ·áÇöÀåÀº ¾îµðÀΰ¡?

º´¿ø ³×Æ®¿öÅ©, Àü¹® Ŭ¸®´Ð, ÀÏÂ÷ Áø·á ¼¾ÅÍ, ÀçÅÃÀÇ·á ¼­ºñ½º Á¦°øÀÚ µî Àü ¼¼°èÀûÀ¸·Î ȯÀÚ Âü¿© ±â¼ú µµÀÔÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ºÏ¹Ì¿Í À¯·´Àº µðÁöÅÐ Çコ ÅõÀÚ¸¦ ¼±µµÇϰí ÀÖÀ¸¸ç, Á¾ÇÕ ÀÇ·á ½Ã½ºÅÛÀÌ ¿£ÅÍÇÁ¶óÀÌÁî±Þ ȯÀÚ Âü¿© Ç÷§ÆûÀ» µµÀÔÇϰí ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå¿¡¼­´Â ½º¸¶Æ®Æù »ç¿ë È®´ë, ¿ø°ÝÀÇ·á ÀÌ´Ï¼ÅÆ¼ºê, Á¤ºÎÀÇ µðÁöÅÐ ÀÇ·á ÀÎÇÁ¶ó¿¡ ´ëÇÑ °ü½É µîÀ» ¹è°æÀ¸·Î µµÀÔÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

¸¸¼ºÁúȯ °ü¸® ÇÁ·Î±×·¥, Ãâ»ê °ü¸®, Á¤½Å°Ç°­ ¼­ºñ½º, ¼ö¼ú ÈÄ È¸º¹ °ü¸® µîÀº ȯÀÚ Âü¿© µµ±¸°¡ ¼øÀÀµµ¿Í °á°ú¸¦ ÃøÁ¤ÇÒ ¼ö ÀÖ°Ô °³¼±ÇÑ ºÐ¾ß Áß ÇϳªÀÔ´Ï´Ù. ÀÇ·á º¸Çè»ç ¹× Ã¥ÀÓÀÇ·á±â°üµµ Âü¿© Ç÷§ÆûÀ» ÅëÇÕÇÏ¿© Áý´Ü °Ç°­ ÀÌ´Ï¼ÅÆ¼ºê¸¦ Áö¿øÇϰí, ÇÇÇÒ ¼ö ÀÖ´Â ÀçÀÔ¿øÀ» ÁÙÀ̱â À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. COVID-19 »çÅ´ ȯÀÚ¿ÍÀÇ Áö¼Ó°¡´ÉÇÑ ±³·ù ¸ðµ¨·Î¼­ °¡»ó Áø·á¿Í ¿ø°Ý Âü¿©ÀÇ °¡Ä¡¸¦ ´õ¿í ÀÔÁõÇß½À´Ï´Ù.

ȯÀÚ Âü¿© ±â¼ú ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁý´Ï´Ù.

ȯÀÚ Âü¿© ±â¼ú ½ÃÀåÀÇ ¼ºÀåÀº °¡Ä¡ ±â¹Ý ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ¿ø°Ý Ä¿¹Â´ÏÄÉÀ̼ǿ¡ ´ëÇÑ ¼±È£µµ Áõ°¡, µðÁöÅÐ ÀÇ·á ±â·ÏÀÇ È®»ê µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ¹ß»ýÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÇ·á ¼­ºñ½º Á¦°øÀÚµéÀº ȯÀÚ Á¢±ÙÀ» °£¼ÒÈ­ÇÏ°í ¹«´Ü°á¼®·üÀ» ³·Ã߸ç, °¡»ó ¹× ¹°¸®Àû ȯ°æ¿¡¼­ Áø·áÀÇ ¿¬¼Ó¼ºÀ» Áö¿øÇÏ´Â Ç÷§Æû¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ¿þ¾î·¯ºí ±â±â, º¸¾È ¸Þ½Ã¡ ½Ã½ºÅÛ, °Ç°­ ÄÚĪ µµ±¸¿ÍÀÇ ÅëÇÕÀ¸·Î ±â´É¼º°ú »ç¿ëÀÚ Âü¿©°¡ È®´ëµÇ°í ÀÖ½À´Ï´Ù.

¸¸¼ºÁúȯÀÇ ÀÚ°¡ °ü¸®, °í·ÉÈ­ »çȸ °ü¸®, ¿¹¹æÀû °Ç°­ ÃßÀûÀÇ Çʿ伺À¸·Î ÀÎÇØ ¾ç¹æÇâ ȯÀÚ ¸ÂÃãÇü Ç÷§ÆûÀÇ °³¹ßÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ºê·Îµå¹êµå¿Í ¸ð¹ÙÀÏ ¿¬°áÀÇ ÆíÀǼº Çâ»óÀ¸·Î ¼­ºñ½º ¼Ò¿Ü Áö¿ª¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ °³¼±µÇ°í, µðÁöÅÐ ÀÇ·á ¼­ºñ½º Á¦°ø¿¡ ´ëÇÑ ±ÔÁ¦Àû Áö¿øÀ¸·Î ÀÎÇØ º¸´Ù ±¤¹üÀ§ÇÑ Ç÷§Æû äÅÃÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ¶ÇÇÑ, °­È­µÈ ºÐ¼® ±â´ÉÀ» ÅëÇØ ÀÇ·á ¼­ºñ½º Á¦°øÀÚ´Â Âü¿© ÁöÇ¥¸¦ ÃßÀûÇÏ°í º¸´Ù È¿°úÀûÀ¸·Î °³ÀÔÀ» Á¶Á¤ÇÒ ¼ö ÀÖ½À´Ï´Ù.

ºÎ¹®

±¸¼º¿ä¼Ò(¼ÒÇÁÆ®¿þ¾î ±¸¼º¿ä¼Ò, ¼­ºñ½º ±¸¼º¿ä¼Ò, ±âŸ ±¸¼º¿ä¼Ò), µô¸®¹ö¸® ¸ðµå(¿ÂÇÁ·¹¹Ì½º µô¸®¹ö¸® ¸ðµå, À¥ ¹× Ŭ¶ó¿ìµå ±â¹Ý µô¸®¹ö¸® ¸ðµå), Å×¶óÇÇ ¿µ¿ª(¸¸¼ºÁúȯ Å×¶óÇÇ ¿µ¿ª, ÇÇÆ®´Ï½º Å×¶óÇÇ ¿µ¿ª, ¿©¼º °Ç°­ Å×¶óÇÇ ¿µ¿ª, Á¤½Å°Ç°­ Å×¶óÇÇ ¿µ¿ª, ±âŸ Å×¶óÇÇ ¿µ¿ª)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°è °íÀ¯ÀÇ SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Patient Engagement Technology Market to Reach US$80.4 Billion by 2030

The global market for Patient Engagement Technology estimated at US$27.5 Billion in the year 2024, is expected to reach US$80.4 Billion by 2030, growing at a CAGR of 19.6% over the analysis period 2024-2030. Software Component, one of the segments analyzed in the report, is expected to record a 19.0% CAGR and reach US$44.8 Billion by the end of the analysis period. Growth in the Service Component segment is estimated at 20.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$7.5 Billion While China is Forecast to Grow at 26.3% CAGR

The Patient Engagement Technology market in the U.S. is estimated at US$7.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$18.8 Billion by the year 2030 trailing a CAGR of 26.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.7% and 17.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 16.4% CAGR.

Global Patient Engagement Technology Market - Key Trends & Drivers Summarized

Why Is Patient Engagement Technology Becoming Foundational to Modern Healthcare Delivery?

Patient engagement technology refers to digital tools and platforms that facilitate two-way communication between patients and healthcare providers, aiming to improve health outcomes through informed decision-making and active participation in care. These technologies include patient portals, mobile health apps, automated reminders, virtual consultation platforms, and remote monitoring interfaces. Their core function is to keep patients informed, motivated, and involved in their care journey-across prevention, diagnosis, treatment, and follow-up stages.

As healthcare systems shift from volume-based to value-based care models, patient engagement is being recognized as a critical driver of care quality, compliance, and resource efficiency. Technology now supports tasks such as appointment scheduling, personalized education, medication adherence tracking, and access to test results. The ability to empower patients while reducing administrative burden is encouraging providers to embed engagement tools within clinical workflows, particularly in outpatient and chronic care settings.

How Are Engagement Tools Evolving Through Integration, Automation, and Personalization?

Advancements in digital health platforms are enabling patient engagement tools to become more integrated, intelligent, and adaptive. Interoperability with electronic health records (EHRs) allows patients to access their records and communicate directly with providers. Mobile apps and wearables are being designed with real-time feedback and behavior tracking features, making daily health management more convenient and data-driven.

AI-powered chatbots, virtual health assistants, and voice-based interfaces are being deployed to provide continuous patient support and reduce dependency on in-person visits. Personalized communication and educational content based on patient history, conditions, or preferences are improving relevance and response rates. Automation of reminders, intake forms, and satisfaction surveys helps streamline clinical administration while maintaining a connected patient experience. Multi-language support and accessibility features are also expanding inclusivity and engagement in diverse populations.

Where Is Demand Increasing and Which Care Settings Are Prioritizing Patient Engagement?

Adoption of patient engagement technology is accelerating globally across hospital networks, specialty clinics, primary care centers, and home health providers. North America and Europe lead in digital health investment, with integrated health systems deploying enterprise-grade patient engagement platforms. Asia-Pacific markets are witnessing increased adoption, driven by expanding smartphone usage, telemedicine initiatives, and government focus on digital health infrastructure.

Chronic disease management programs, maternity care, mental health services, and post-surgical recovery care are among the areas where patient engagement tools are delivering measurable improvements in adherence and outcomes. Health insurers and accountable care organizations are also integrating engagement platforms to support population health initiatives and reduce avoidable readmissions. The COVID-19 pandemic has further validated the value of virtual care and remote engagement as sustainable models for patient interaction.

Growth in the Patient Engagement Technology market is driven by several factors…

Growth in the patient engagement technology market is driven by factors such as rising demand for value-based healthcare, growing preference for remote communication, and widespread adoption of digital health records. Providers are investing in platforms that streamline patient access, reduce no-show rates, and support continuity of care across virtual and physical settings. Integration with wearable devices, secure messaging systems, and health coaching tools is expanding functionality and user involvement.

The need for chronic disease self-management, aging population care, and preventive health tracking is accelerating development of interactive and patient-specific platforms. Increased availability of broadband and mobile connectivity is improving access in underserved areas, while regulatory support for digital care delivery is enabling broader platform adoption. Enhanced analytics capabilities are also allowing providers to track engagement metrics and tailor interventions more effectively.

SCOPE OF STUDY:

The report analyzes the Patient Engagement Technology market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Component (Software Component, Service Component, Other Components); Delivery Mode (On-Premise Delivery Mode, Web & Cloud-based Delivery Mode); Therapy Area (Chronic Diseases Therapy Area, Fitness Therapy Area, Women's Health Therapy Area, Mental Health Therapy Area, Other Therapy Areas)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â